Paul J Kleindl

US Patent:

20100323973, Dec 23, 2010

Filed:

Jun 25, 2008

Appl. No.:

12/666712

Inventors:

Christopher Paul Leamon - West Lafayette IN, US
Iontcho Radoslavov Vlahov - West Lafayette IN, US
Hari Krishna R. Santhapuram - West Lafayette IN, US
Paul Joseph Kleindl - Lebanon IN, US
Yu Wang - Fishers IN, US
Fei You - West Lafayette IN, US

International Classification:

A61K 38/14
C07K 5/093
A61K 38/06
A61K 38/08
A61P 35/00
C07K 7/06
C07K 7/64
A61K 38/12
C07K 9/00
A61P 31/04
A61P 31/12
A61P 31/10
A61P 33/10
A61P 33/04
A61P 33/02

US Classification:

514 209, 530331, 514 219, 514 218, 530330, 530329, 514 217, 514 216, 530328, 530321, 514 211, 530322

Abstract:

Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and/or treating diseases and disease states caused by pathogenic cell populations.

US Patent:

20120022245, Jan 26, 2012

Filed:

Oct 16, 2009

Appl. No.:

13/124408

Inventors:

Philip Stewart Low - West Lafayette IN, US
Mini Thomas - West Lafayette IN, US
Christopher Paul Leamon - West Lafayette IN, US
Iontcho Radoslavov Vlahov - West Lafayette IN, US
Paul Joseph Kleindl - Lebanon IN, US
Longwu Qi - West Lafayette IN, US

Assignee:

PURDUE RESEARCH FOUNDATION - West Lafayette IN
ENDOCYTE, INC. - West Lafayette IN

International Classification:

C07H 21/02
C07K 9/00
C07H 21/00

US Classification:

536 245, 536 231, 530322

Abstract:

The present invention relates to compounds, compositions, kits, and methods of use in targeting nucleotides, such as siRNA's, to cancer cells or to immune system cells involved in inflammation. More particularly, the invention is directed to receptor binding ligand-nucleotide delivery conjugates for use in specifically targeting the conjugates to cancer cells or to immune system cells, methods of treatment with these conjugates, methods of preparation of these conjugates, and methods of reducing the expression of a gene in vitro or in vivo with the conjugates described herein.

US Patent:

20130137139, May 30, 2013

Filed:

Aug 5, 2011

Appl. No.:

13/814336

Inventors:

Iontcho Radoslavov Vlahov - West Lafayette IN, US
Michael Groaning - West Lafayette IN, US
Paul Joseph Kleindl - Lebanon IN, US
Hari Krishna R. Santhapuram - West Lafayette IN, US
Fei You - West Lafayette IN, US
Kevin Yu Wang - Zionsville IN, US
Katheryn Marie Stanford - Lafayette IN, US
Allen Ritter - Lafayette IN, US
Paul Christopher Leamon - West Lafayette IN, US

Assignee:

ENDOCYTE, INC. - West Lafayette US

International Classification:

C07K 5/02

US Classification:

435 681, 530330

Abstract:

Tubulysins are a series of naturally occurring cytotoxic agents that are of interest as anticancer therapeutic agents. Processes and intermediates useful for preparing naturally occurring and non-naturally occurring tubulysins and analogs and derivatives thereof are described.

US Patent:

20130267522, Oct 10, 2013

Filed:

Feb 27, 2013

Appl. No.:

13/779501

Inventors:

Deborah Knapp - West Lafayette IN, US
Deepika Dhawan - West Lafayette IN, US
Philip S. Low - West Lafayette IN, US
Paul Joseph Kleindl - Lebanon IN, US
Iontcho R. Vlahov - West Lafayette IN, US

Assignee:

Endocyte, Inc. - West Lafayette IN
Purdue Research Foundation - West Lafayette IN

International Classification:

A61K 31/519

US Classification:

514249, 435 723

Abstract:

The invention relates to methods and uses for the treatment of a cancer. In particular, the invention relates to the use of a folate-vinca conjugate to treat urinary bladder cancer (e.g., invasive transitional cell carcinoma (InvTCC)).

US Patent:

20140073761, Mar 13, 2014

Filed:

Mar 5, 2013

Appl. No.:

13/785542

Inventors:

Iontcho R. Vlahov - West Lafayette IN, US
Hari Krishna R. Santhapuram - West Lafayette IN, US
Paul J. Kleindl - Lebanon IN, US
Kevin Yu Wang - Zionsville IN, US
Fei You - West Lafayette IN, US

Assignee:

ENDOCYTE, INC. - West Lafayette IN

International Classification:

A61K 47/48

US Classification:

530317, 544258, 530330, 530329, 530328

Abstract:

Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and/or treating diseases and disease states caused by pathogenic cell populations.

US Patent:

20140080175, Mar 20, 2014

Filed:

Mar 15, 2013

Appl. No.:

13/841349

Inventors:

Hari Krishna R. SANTHAPURAM - West Lafayette IN, US
Paul J. KLEINDL - Lebanon IN, US
Christopher P. LEAMON - West Lafayette IN, US
Fei YOU - West Lafayette IN, US

Assignee:

ENDOCYTE, INC. - West Lafayette IN

International Classification:

C07K 7/02
C07K 5/02

US Classification:

435 681, 530323, 530331

Abstract:

The invention described herein pertains to processes for preparing tubulysin derivatives, conjugates of tubulysins, and intermediates therefore.

US Patent:

6348633, Feb 19, 2002

Filed:

Jul 2, 2001

Appl. No.:

09/806745

Inventors:

Mark L. Robin - West Lafayette IN
Charles J. Mazac - Zionsville IN
Leonard J. Chyall - Lafayette IN
Paul Kleindl - Madison WI

Assignee:

PCBU Services, Inc. - Wilmington DE

International Classification:

C07C 1908

US Classification:

570129, 570149, 523462, 524462

Abstract:

Bromine containing 1,2-bis(phenyl)difluoromethane derivatives, a method for their preparation and their use in flame retardant compositions.

US Patent:

20210069340, Mar 11, 2021

Filed:

Jul 16, 2020

Appl. No.:

16/930590

Inventors:

- West Lafayette IN, US
Christopher Paul LEAMON - West Lafayette IN, US
Fei YOU - West Lafayette IN, US
Yingjuan J. LU - West Lafayette IN, US
Paul Joseph KLEINDL - Lebanon IN, US

International Classification:

A61K 47/65
A61K 47/55
C07D 487/04
C07K 7/02
C07K 9/00
C07K 5/00
C07K 5/113
C07K 19/00
C07K 7/06
A61P 19/02
A61P 29/00
A61K 31/519

Abstract:

The present invention relates to compositions and methods for use in targeted drug delivery. More particularly, the invention is directed to cell-surface receptor binding conjugates containing hydrophilic spacer linkers for use in treating disease states caused by pathogenic cell populations and to methods and pharmaceutical compositions that use and include such conjugates.